Once-yearly zoledronic acid in hip fracture prevention

Clinical Interventions in Aging

Volumn 4, Issue 1, 2009, Pages 153-164

  Demontiero, Oddom ^a,b   Duque, Gustavo ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEPEAN HOSPITAL   (Australia)

Author keywords

Elderly; Hip fracture; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

AGE DISTRIBUTION; AGING; APOPTOSIS; ARTHRALGIA; BONE DENSITY; BONE MASS; BONE PAIN; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FRACTURE; FRAGILITY FRACTURE; FRAIL ELDERLY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FUNCTION; LOADING DRUG DOSE; MAGNESIUM BLOOD LEVEL; MORTALITY; MUSCULOSKELETAL PAIN; MYALGIA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; POTASSIUM BLOOD LEVEL; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HIP FRACTURES; HUMANS; IMIDAZOLES; MIDDLE AGED;

EID: 66249138803     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Raisz L. Pathogenesis of osteoporosis: concepts, confl icts, and prospects. J Clin Invest. 2005;115(12):3318-3325.
2. Clowes J, Eastell R. The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14(2):213-232.
3. Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-475.
4. Siris E, Miller P, Barrett-Connor E, et al. Identifi cation and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. Results From the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815-2822.
5. Wilkins C, Birge S. Prevention of osteoporotic fractures in the elderly. Am J Med. 2005;118(11):1190-1195.
6. Reginster J, Burlet N. Osteoporosis: A still increasing prevalence. Bone. 2006;38(2 Suppl 1):S4-S9.
7. Cole Z, Dennison E, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep. 2008;10(2):92-96.
8. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16 Suppl 2:S3-S7.
9. Cooper C, Atkinson E, Jacobsen S, O'Fallon W, Melton Lr. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137(9):1001-1005.
10. Farahmand B, Michaelsson K, Ahlbom A, Ljunghall S, Baron J. Survival after hip fracture. Osteoporos Int. 2005;16:1583-1590.
11. Haentjens P, Boonen S. Excess mortality after hip fracture among postmenopausal women and ageing men: evidence from data searches and life-table analyses for gender-related differences in absolute risk of death after hip fracture. Osteporosis Int. 2007;18 Suppl 1:S5-S6.
12. Torgerson D, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis. 1998;57(6):378-379.
13. Kamel H, Hussain M, Tariq S, Perry H, Morley J. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med. 2000;109(4):326-328.
14. Kamel H, Duthie E. The underuse of therapy in the secondary prevention of hip fractures. Drugs Aging. 2002;19(1):1-10.
15. Andrade S, Majumdar S, Chan K, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163(17):2052-2057.
16. Solomon D, Finkelstein J, Katz J, Mogun H, Avorn J. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003;115(5):398-400.
17. Colón-Emeric C, Lyles K, House P, et al. Randomized trial to improve fracture prevention in nursing home residents. Am J Med. 2007;120(10):886-892.
18. Klotzbuecher C, Ross P, Landsman P, Abbott Tr, Berger M. Patients with prior fractures have an increased risk of future fractures:a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721-739.
19. Kanis J, Johnell O, Laet CD, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375-382.
20. Center J, Bliuc D, Nguyen T, Eisman J. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297:387-394.
21. Friesendorff MV, Besjakov J, Åkesson K. Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res. 2008;23(11):1832-1841.
22. Hamlet W, Lieberman J, Freedman E, Dorey F, Fletcher A, Johnson E. Influence of health status and the timing of surgery on mortality in hip fracture patients. Am J Orthop. 1997;26(9):621-627.
23. Center J, Nguyen T, Schneider D Sambrook P, Eisman J. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878-882.
24. Bhattacharyya T, Iorio R, Healy W. Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg Am. 2002;84-A(4):562-572.
25. Magaziner J, Fredman L, Hawkes W, et al. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol. 2003;157(11):1023-1031.
26. Russell R. Determinants of structure-function relationships among bisphosphonates. Bone 2007;40(5):S21-S25.
27. Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab. 2007;92(3):747-753.
28. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med. 2008;264(4):315-332.
29. Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
30. Lyles K, Colon-Emeric C, Magaziner J, et al. Zoledronic acid and clinical features and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-1809.
31. Dunford J, Thompson K, FP FC, et al. Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235-242.
32. Rodan G, Fleisch H. Bisphosphonates: mechanism of actions. J Clin Invest. 1996;97:2692-2696.
33. Lehenkari P, Kellinsalmi M, Napankangas J, et al. Further insight into mechanism of action of clodronate:inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenosine containing metabolite. Mol Pharmacol. 2002;61(5):1255-1262.
34. Frith J, Monkkonen J, Auriola S, Monkkonen H, Rogers M. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001;44(9):2201-2210.
35. Russell R. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006;1068:367-401.
36. Bergstrom J, Bostedor R, Masarachia P, Reszka A, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000;373(1):231-241
37. Li E, Davis L. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther. 2003;25(11):2669-2708.
38. Green J. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol. 2001;28(2 Suppl 6):4-10.
39. Benford H, McGowan N, Helfrich M, Nuttall M, Rogers M. Visualization of bisphosphonateinduced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28(5):465-473.
40. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60(11):2949-2954
41. Nancollas G, Tang R, Guide S, et al. Mineral binding affinities and zeta potentials of bisphosphonates. J Bone Miner Res. 2002; 17 Suppl 1:S368.
42. Nancollas G, Tang R, Phipps R, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyappetite. Bone. 2006;38(5):617-627.
43. Hornby S, Evans G, Hornby S, Pataki A, Glatt M, Green J. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int. 2003;72(4):519-527.
44. Binkley N, Kimmel D, Bruner J, et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res. 1998;13(11):1775-1782.
45. Novartis, Reclast (zoledronic acid). East Hanover, NJ August 2007.
46. Green J, Muller K, Jaeggi K. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;5(9):745-751.
47. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228-1236
48. Boonen S, Sellmeyer D, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74:641-648.
49. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41(1):122-128.
50. Reid I, Brown J, Burckhardt P, et al. Intravenous Zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-661.
51. Patrick M, Purcell WB, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. MJA. 2005;182(8):417-418.
52. Vieillard M, Maes J, Penel G, et al. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint, Bone, Spine: Revue du Rhumatisme. 2008;75(1):34-40.
53. Brooks J, Gilson A, Sindler A, Ashman S, Schwartz K, Nikitakis N. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(6):780-786.
54. Mashiba T, Mori S, Burr D, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab. 2005;23 Suppl:S36-S42.
55. Komatsubara S, Mori S, Mashiba T, et al. Long term treatment of incdronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res. 2003;18:512-520.
56. Allen M, Iwata K, Phipps R, others a. Residroante and alendroante similarly suppress remodeling and increase microdamage in beagles after 1 year of treatment at clinical doses. 27th Annual Meeting of the American Society for Bone and Mineral Research. Nashville, Tennessee, USA: J Bone Miner Res. 2005:S22.
57. Recker R, Ensrud K, Diem S, et al. Normal Bone Histomorphometry and 3D microarchitecture after 10 years alendronate treatment of post-menopausal women. 26th Annual meeting of the American Society for Bone and Mineral Research. Seattle, Washington, USA. 2004:S45.
58. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zole-dronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40(5):1238-1243.
59. Borba V, Paz-Filho G. Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int J Clin Pract. 2007;61(6):1058-1062.
60. Devogelaer J, Brown J, Burkhardt P, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int. 2007;18(9):1211-1218.
61. Bruyere O, Brandi M, Burlet N, et al. Post-fracture management of patients with hip fracture: a perspective. Curr Med Res Opin. 2008;24(10):2841-2851.
62. Duque G. Intravenous zoledronic acid reduced new clinical fractures and deaths in patients who had recent surgery for hip fracture. ACP J Club. 2008;148(2):40.
63. Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541.
64. Cranney A, Waldegger L, Zytaruk N, et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev. 2003(4):CD004523.
65. Duque G, Demontiero O, Troen B. The prevention and treatment of senile osteoporosis and hip fractures. Minerva Medica (in press).
66. Silverman S. Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am. 2006;32(4):721-731.
67. Yood R, Emani S, Reed J, Lewis B, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14(12):965-968.
68. Siris E, Harris S, Rosen C, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-1022.
69. Colón-Emeric C, Lyles K, Levine D, et al. Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int. 2007;18(4):553-559.
70. Wells G, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008(Issue 1. Art. No.: CD001155).
71. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD004523.